Avanza Bank Holding AB: 2 directors

Two Directors at Avanza Bank Holding AB bought 784 shares at between 327.400SEK and 339.000SEK. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...

Investor AB: 2 directors

Two Directors at Investor AB bought 13,980 shares at between 282.400SEK and 286.790SEK. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...

New CEO, new execution

Q1: New CEO with track record

Pipeline the main trigger in 2025

Patience is a virtue

Q4: Year-end sales bump

A closer look at GBS and NiceR

Solid GBS IGOS efficacy analysis

Initiates Ph 2 in Crigler-Najjar syndrome

Keeping the momentum going

Q3: Strong sales offset by heavy provision

Takeaways from NiceR call

NiceR (5487) is nicer than Imlifidase

Stable quarter but time to grow in H2

EU adj. sales development neutral. Cash burn to improve in H2 after one-offs in Q2. Revising our model: BUY, TP SEK 88 (98).

Q2: a rainy spring

End of coverage

From 5th February, we will no longer include in our research universe:Adaptimmune, ALK, argenx, Autolus, Cellectis, Galapagos, Hansa Biopharma, Heidelberg Pharma, Immatics, Immunocore, Ipsen, Moonlake Immunotherapeutics, Pharvaris, UCB, Vivoryon Therapeutics, Zealand Pharma, Nicox, GenSight Biologi

More execution challenges, downgrading to SELL

Hansa recently announced the first results from its 2nd gen product, HNSA-5487, which did not actually give an answer to its repeat dosing potential and likely will not be clear even with all data analysed in 2024. While we believe that HNSA-5487 is the real value in the company, the lack of clarit

Coverage update

Given team and strategy changes, Alex Cogut is now assuming coverage of Achilles Therapeutics, Adaptimmune Therapeutics, Autolus, Calliditas, Cellectis, Galapagos, GenSight, Hansa Biopharma, Heidelberg Pharma, Immunocore, Innate Pharma, Sesorion and ValerioWe drop coverage of Celyad Oncology BioNte

Bryan, Garnier & Co Healthcare Daily | Hansa, MoonLake